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Abstract
Multimorbidity is widely recognized as having adverse effects on health and wellbeing and may threaten the ability of older adults to live 
independently. Much of what is known about multimorbidity rests on research that has largely focused on one point in time, or from a static 
perspective. Given that there remains a lack of agreement in the field on how to standardize multimorbidity definitions and measurement, it is 
not surprising that analyzing and predicting multimorbidity development, progression over time, and its impact are still largely unaddressed. 
As a result, there are important gaps and challenges to measuring and studying multimorbidity in a longitudinal context. This Research 
Practice perspective summarizes pressing challenges and offers practical steps to move the field forward.
Keywords: Multimorbidity, Comorbidity, Multiple chronic diseases, Chronic diseases, Longitudinal
Multimorbidity—commonly defined as two or more coexisting 
chronic diseases—is a major clinical and public health concern be-
cause it is prevalent—approximately two-thirds of middle-aged and 
older adults in the United States have multimorbidity—costly, and 
burdensome (1). There has been a concerted effort to shift clinical 
practice away from solely focusing on individual diseases and in-
stead consider multiple diseases as they co-occur in patients (2,3). 
Still, there is much to be uncovered and specified prior to develop-
ing clinical practice guidelines for managing patients with various 
types of multimorbidity presentation. A seminal report from the U.S. 
Department of Health and Human Services and the commentaries 
that followed identified multiple remaining gaps (2,4). These gaps 
involve several areas where clinical and research practice is tasked 
to: (a) increase the evidence based on the epidemiology of multi-
morbidity; (b) ensure that individuals with multimorbidity are in-
cluded in clinical trials; (c) incorporate a patient-centered approach 
in assessing the impact of multimorbidity on patients’ lives; and (d) 
identify disparities in multimorbidity and multimorbidity-related 
impacts on quality of life among vulnerable population subgroups.
The association between escalating chronic disease burden and 
health outcomes has been widely documented (5–8), but not all com-
binations of illness have equal effects. Recent efforts center on identi-
fying disease combinations with serious health-related consequences, 
such as premature disability and mortality (9–14). Still, the nature 
of multimorbidity progression over time is unclear; there has been 
comparatively little work done to understand the complex nature of 
changes in multimorbidity on important outcomes throughout the 
life span (15). Understanding how multimorbidity evolves into de-
bilitation and identifying factors that accelerate or slow this progres-
sion is of practical, clinical, and methodological significance.
The field of multimorbidity research continues to grapple with 
important questions on standardizing multimorbidity measure-
ment—for example, which chronic conditions should be included in 
the numerator? Or, should this inclusion list instead be flexible and 
contingent on the research question and aim of the study?—with no 
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consensus on how to define multimorbidity. Many, including our-
selves, have adopted a useful framework to outline the scope of mul-
timorbidity measurement and rationale for considering a core set 
of chronic conditions that are persistent, prevalent, and important 
age-related diseases (3). Separate, though related and important, are 
geriatric syndromes and the work yet to be done to parse the rela-
tionship between multimorbidity progression and syndromes such as 
frailty, incontinence, falls, and delirium (9,15).
Current lack of consensus should not preclude us from looking 
ahead and strategizing about the issues involved with assessing 
multimorbidity changes over time. A critical yet missing piece in 
the conversation is a discussion of the methodological challenges 
facing researchers who seek to study multimorbidity from a longi-
tudinal perspective and devising strategies to make headway in this 
effort. Thus far, multimorbidity measurement—as a total count 
or as combinations or patterns of disease—has focused on cross-
sectional, static measurement issues. Longitudinal approaches 
to studying multimorbidity may offer several opportunities and 
insights over cross-sectional approaches; however, measurement 
becomes more challenging when considering multimorbidity in a 
time-varying perspective (Table 1). In fact, the specific challenges 
and considerations for logically-consistent and reliable measure-
ment are not evident until we begin to assess multimorbidity longi-
tudinally. For instance, a full and consistent reporting and capture 
of diagnoses for a patient’s entire health history (birth to death) is 
difficult to ascertain given the complexities of fragmented health 
care systems, differences in health care seeking behavior underly-
ing “access” to diagnoses, and attrition in population surveys.
In order to advance the science and practice of studying mul-
timorbidity development and progression, challenges to longitu-
dinal multimorbidity assessment need to be outlined and effective 
strategies devised. Detailing these considerations and forming 
standardized research practices to address these concerns is not 
only timely but it is also necessary. The next breakthrough in our 
understanding of multimorbidity will come from uncovering how 
chronic diseases accumulate and interact over time to affect different 
segments of our population to different degrees and with different 
consequences. In addressing the challenges of evaluating the longitu-
dinal progression of multimorbidity, we identify three critical areas 
to prioritize: (a) consistent longitudinal assessment of multimorbid-
ity component diseases and their accounting; (b) the relative severity 
of diseases, individually and together; and (c) the representative-
ness of studied populations. The last point is particularly crucial: to 
address clinical and policy needs, research must focus on high-risk 
populations, such as underrepresented racial and ethnic minorities 
and older adults, to overcome a variety of methodological biases 
and extend the generalizability of this research. These populations 
are currently not well represented in curated data sets, in particular 
those from clinical trials. Thus, to make progress, we must surmount 
data and methodological hurdles inherent to analyzing changes in 
multimorbidity over time. Below, we expand on these three pressing 
challenges to measuring, analyzing, and assessing the population im-
pact of multimorbidity from a longitudinal perspective and offer in-
sights to make headway.
Longitudinal Inconsistency of Chronic Disease 
Tracking
Identifying chronic disease patterns in a rigorous manner forms 
the most necessary condition in assessing multimorbidity burden 
or  combinations, and changes over  time. Evidence shows that pa-
tients, in particular those belonging to racial and ethnic minority 
groups, inconsistently report their chronic diseases over time in lon-
gitudinal health interview surveys and the degree of inconsistency 
Table 1. How Pressing Challenges to Studying Multimorbidity Over Time Manifest in a Cross-sectional Versus Longitudinal Context
Main Challenges Cross-sectional Context Longitudinal Context
1. Longitudinal 
inconsistency
(−) Cannot measure: 
May not be aware of inconsistent patterns if only 
examining one point in time.
(+) Can measure: 
Aware of issue if data are examined before and 
after to assess rates and pattern of responses, 
and allows for clarification with possible 
algorithm development and validation.
Implications: Unclear consequences to prevalence 
estimates.
Implications: May improve precision of 
prevalence estimates.
2. Severity (+/−) Limited measurement: 
Can assess severity linked to function or another patient-
centered health outcome at one point in time only.
(+) Can measure: 
Relationship between severity and 
multimorbidity becomes more evident as 
changes in multimorbidity can be linked to 
changes in function and other patient-centered 
changes in health.
Implications: No clarity on temporality: onset, timing, 
development, or progression.
Implications: Improves inference between 
timing of morbidity risks and health outcomes.
3. Underrepresentation (−) Cannot measure: 
No way to identify who is excluded at any particular 
point-in-time assessment.
(+) Can measure: 
Depending on length of follow-up, can 
examine data before and after to ascertain 
missingness, correlates with missingness, 
and multimorbidity patterns prior to loss or 
censoring.
Implications: Unclear consequences to prevalence 
estimates, and evaluations of effectiveness of treatments.
Implications: Improves accuracy of 
population-level impact of programs and 
treatments.
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varies widely by disease and by race/ethnicity (16). Yet, population-
based health interview surveys have long been used as dependable 
tools to track accumulation of disease burden at the individual level 
and monitor population health. Self-reporting of chronic diseases re-
lies on consistent access to a usual source of care, as well as health 
literacy and comprehension of disease processes, which may vary 
by education, socioeconomic status, and cognitive ability. Thus, in 
follow-up interviews, individuals may not consistently report diag-
noses due to fragmented or discontinuous health care coverage, 
poor recall, difficulty in understanding the chronic nature of their 
diseases, confusion between asymptomatic or well-controlled disease 
and no-disease status, or poor cognitive function.
Other sources of chronic disease ascertainment are simi-
larly problematic: electronic health record data are typically not 
designed for research purposes, may not consistently record diag-
noses in follow-up encounters, or may reflect changes in diag-
nostic criteria or diagnostic procedures ordered for suspected or 
unconfirmed diagnoses; thus, presenting difficulties in discerning 
disease status over time. The frequency of assessing chronic con-
ditions also is not standardized and influences measures of rate 
and patterns of accumulation. As a result, longitudinal patterns of 
chronic disease for a given patient may be clinically-consistent (ie, 
always affirmative, always negative, or negative then affirmative) 
or clinically-inconsistent (ie, affirmative then negative), hindering, 
or at the very least complicating assessments of multimorbidity 
progression (16).
Opportunities to Make Headway
Because incontrovertible, valid, and reliable methods to “adjust” 
for inconsistent reporting of chronic disease status currently do 
not exist, marshaling data resources to triangulate information on 
chronic disease status are essential. In particular, these resources 
need to be enhanced in populations with higher rates of misreport-
ing. With the integration of diverse sources of information—includ-
ing medication use, laboratory values and other diagnostic tests, and 
practitioner- and patient-generated health data—consistent tracking 
can be achieved through assessments and adjustments for data qual-
ity, and through sensitivity analyses for the effects of inconsistent 
reporting. It is important to note that most clinical data sources may 
not be a gold standard for ascertaining a comprehensive record and 
history of a patient’s diagnoses. For instance, some chronic condi-
tions, such as dementia, are defined by functional decrements; thus, 
function may be integrally linked to disease definition and may 
be difficult to ascertain in clinical data alone. Relying on one data 
source in isolation of complementary data sources limits us from lev-
eraging a variety of information and perspectives into diagnoses. In 
the long term, there is a need to develop valid and reliable algorithms 
and procedures to maximize—through integration, consolidation, 
and evaluation—information from the patient, clinical record, and 
administrative data sources.
Assessing Disease Severity
Another complex issue involves ascertaining disease severity 
across the multitude of chronic disease patients with multimor-
bidity have—that is, assessing overall severity for a particular 
multimorbidity combination (17). Capturing time-varying disease 
severity in the context of multimorbidity is far more complicated 
than for single diseases because (a) valid and reliable systems to 
classify severity vary by disease and disease-stage; (b) sequelae/
complications may be attributable to multiple conditions; (c) 
interactions between diseases may increase severity/acuity and 
symptom burden, as well as complicate the treatment of other 
diseases in the combination; and (d) severity may not be mono-
tonically increasing, as patients who engage in interventions may 
experience reductions in the severity of one or multiple compo-
nent diseases. Given the much earlier onset of multimorbidity in 
minority patients, the severity of similar combinations of diseases 
may likely be higher (due to lead time to diagnosis, disease dur-
ation, and likelihood of treatment) among minority patients com-
pared with white patients of similar age.
To date, it has proven operationally and conceptually prohibitive 
to assess severity for diseases, individually and then in combination, 
and determine changes in severity over time. However, assessing 
severity of each individual disease may not provide as much clinical 
clarity as assessing the continuum of impairments, and subclinical/
clinical diseases representing loss of homeostasis (17). In addition, 
the concept of severity in and of itself is important to ascertaining 
progression of multimorbidity: deleterious progression of multimor-
bidity may not be captured by simply specifying nominal changes in 
disease counts over time or newly added diagnoses to a particular 
multimorbidity combination. This is because multimorbidity may 
worsen or progress with no changes in total disease count and may 
occur with further worsening of one or more diseases already in 
combination.
Opportunities to Make Headway
Assessing severity in the context of multimorbidity should account 
for the continuum of disease accumulation and subsequent impair-
ments that presage loss of homeostatic equilibrium, and this may 
differ between racial and ethnic groups. In the long term, we need 
to have to a consistent and valid way to assess severity for individu-
als with multimorbidity and understand how multimorbidity com-
binations of varying severity affect patient’s lives. The way forward 
may be to develop and validate population-sensitive proxy measures 
of multimorbidity “severity” that assess the functional, self-rated 
health, or health-related quality of life consequences of diseases 
added onto multimorbidity combinations. For example, a recently 
developed and validated multimorbidity index weighted to physical 
functioning measures links functional consequences to specific mul-
timorbidity combinations and could provide valuable insights into 
changes in multimorbidity severity over time and across populations 
(18).
Underrepresentation
Inadequate population representation may be the most difficult 
issue. Whether in the form of not capturing underrepresented minor-
ity participants who die prior to study entry (left censoring and 
healthy survivor effects), losing minority patients/participants who 
no longer interact with the health care system or survey (immortal 
time bias or right censoring), or restricting inclusion in prospective 
studies based on language, access, or cognition, the implications are 
vast and problematic. Without more complete population represen-
tation in studies, clinical complexity cannot be reflected. Thus, very 
different recommendations to address health disparities may result. 
For example, many population-based longitudinal surveys start in 
midlife or later, past the point of chronic disease onset in high-risk 
populations; thus, missing critical periods for multimorbidity onset 
and progression in these groups.
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Opportunities to Make Headway
Studies should strive for close representativeness, by race/ethnicity 
and beyond, to the true population and consider whether patient 
databases reflect populations with access to care rather than the 
target population. In the conduct of survey studies, advancing efforts 
to maximize response rates and account for nonrandom attrition are 
also critical to counteracting this issue. New policies, such as those 
applied to NIH-sponsored human subject’s research, encourage in-
clusion of individuals across wider ages of the life span and will help 
to mitigate problems stemming from lack of observation during crit-
ical periods of chronic disease onset (19).
In Summary
Progress on studying multimorbidity development and progression in 
clinically-meaningful and methodologically-reliable ways remains chal-
lenging. This discussion is not a comprehensive list of all of the issues 
involved with examining multimorbidity in a longitudinal fashion, but 
represents a core set of issues to begin to formulate responsive and lo-
gical approaches. We discuss and identify ways to move the field for-
ward, so that we can meet the challenges of caring for clinically-complex 
and vulnerable segments of our population. Recommendations include 
studies to explore both better consistency in multimorbidity reporting 
over time, standardize frequency and timing of assessments to ascertain 
rates, and assess problems with data quality, inaccuracies, and reporting 
biases; to improve the assessment of clinical and functional severity in 
the context of multimorbidity; and to enhance the representativeness 
of populations studied. These will help provide better assessments and 
predictions for the impact of multimorbidity over the life span and may 
uncover ways to improve our tailoring of care to clinically-complex pa-
tients and their priorities, rather than solely to individual conditions.
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